Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130442 · ClinicalTrials.gov registry record · Phase 2
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Cellxpert Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT00130442 is a Phase 2 study that has completed, run by Cellxpert Biotechnology. The registered enrollment target is 134 participants.
The verdict
NCT00130442, a Phase 2 study, has completed, sponsored by Cellxpert Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma. PI-88 blocks new blood vessel growth in tumours (starves it of nutrients) and dacarbazine stops the cancer cells from growing. The results from this study will be analysed to see if it is worthwhile for the two drugs to be tested in future studies involving larger numbers of melanoma patients.
Interventions
- DRUG PI-88 and dacarbazine
- DRUG dacarbazine or DTIC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130442
The ClinicalTrials.gov registry entry for NCT00130442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellxpert Biotechnology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PI-88 and dacarbazine is the first listed.
NCT00130442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130442 about?
NCT00130442 is a clinical study titled "Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma". The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma. PI-88 blocks new blood vessel growth in tumours (starves it of nutrients) and dacarbaz...
What is the current status of trial NCT00130442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2005-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00130442?
The interventions under investigation include: PI-88 and dacarbazine (DRUG), dacarbazine or DTIC (DRUG).
Who is sponsoring clinical trial NCT00130442?
This trial is sponsored by Cellxpert Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.